IPM Take
Schizophrenia treatment is often judged by what disappears: hallucinations, delusions, agitation and hospitalisation. Patients also live with what fails to return.
Motivation, pleasure, social engagement and goal-directed behaviour can remain profoundly impaired even when psychosis is controlled. These negative symptoms shape work, relationships and independence, yet pharmacological options remain limited. The CONVOKE trial matters because a digital intervention was designed directly around that neglected part of the disease rather than simply digitising another clinic appointment. JAMA Network
Executive Summary
A Phase III randomised, double-blind clinical trial published in JAMA Network Open evaluated CT-155, an investigational smartphone-based digital therapeutic, as an adjunct to pharmacotherapy in adults with schizophrenia experiencing motivation and pleasure-related negative symptoms.
The trial randomised 459 participants, with 228 assigned to CT-155 and 231 to a digital control. CT-155 produced a statistically significant improvement in the study’s primary negative-symptom outcome at week 16, with the authors describing the effect as small to moderate and comparable with effects reported for psychosocial or pharmacological interventions in psychiatry. JAMA Network
Adverse events were not increased relative to digital control, and no serious treatment-related adverse events were reported. CT-155 remains investigational. The trial was industry-supported and several authors were affiliated with Boehringer Ingelheim and Click Therapeutics, which should remain visible when interpreting the evidence. JAMA Network
Why it matters
- The most disruptive symptoms of schizophrenia are not always the ones most visible during an acute psychiatric admission. Negative symptoms can leave someone unable to initiate activities, sustain relationships or experience reward even when hallucinations and delusions are controlled.
- A scalable adjunct delivered through a smartphone could potentially reach patients who cannot access intensive psychosocial services. That possibility is attractive, but “digital” cannot automatically be translated into “equitable.” Smartphone access, digital literacy, engagement and clinical integration still determine who benefits.
Psychiatry has built much of schizophrenia care around crisis. Acute psychosis demands attention, and antipsychotic treatment has transformed the ability to control hallucinations, delusions and severe behavioural disturbance. Yet after the crisis settles, many patients remain trapped in a quieter disability that the system is much worse at treating.
Negative symptoms do not make dramatic emergency-room stories. A person may simply stop initiating conversations, pursuing goals, seeing friends or finding pleasure in activities that once mattered. Those losses can be devastating precisely because they are easy to mistake for disengagement or unwillingness.
CT-155 was designed around that gap. It combines evidence-based psychosocial components intended to support reward processing, engagement and goal-directed behaviour, delivered through a smartphone alongside existing pharmacotherapy. In CONVOKE, it produced a statistically significant improvement compared with a digital control rather than merely a no-treatment comparator. JAMA Network
That makes the evidence more interesting, but not complete. The study lasted 16 weeks and occurred within a structured clinical trial environment. Real-world engagement may look different when research visits disappear and the phone competes with everything else in everyday life.
Still, the policy implication is worth taking seriously. Digital psychiatry should not be judged by whether it looks innovative. It should be judged by whether it reaches clinically neglected problems and expands care without lowering evidence standards.
For schizophrenia, the most important advance may not always be suppressing another symptom. It may be helping a person regain enough motivation to participate in life again.
